All In Biotech

Drug Trial Radar · NCT04905602

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administered SHR-1905 in Healthy Subjects and Subjects With Mild Asthma.

Last checked: Nov 19, 2026Latest source record: Oct 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Jun 15, 2021

Primary completion

Oct 9, 2023

Study completion Oct 9, 2023

Sponsor

Sponsor type
Industry
First posted
May 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a phase 1 single dose escalation study of SHR-1905 in healthy subjects and subjects with mild asthma. The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of SHR-1905 in healthy subjects and subjects with mild asthma.

Conditions

  • Asthma

Interventions

  • SHR-1905/placeboDrug

    Drug: SHR-1905 subcutaneous, single dose Drug: Placebo subcutaneous, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: Start of Treatment to end of study (approximately 16 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Xuhui Central Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.